Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome

  • Kim, Kwang-il (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2018.03.12
  • Accepted : 2018.03.21
  • Published : 2018.05.31
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-35. https://doi.org/10.1161/CIRCULATIONAHA.108.829176
  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53. https://doi.org/10.1016/S0140-6736(98)07019-6
  3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89. https://doi.org/10.1056/NEJMoa0806470
  4. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39. https://doi.org/10.1056/NEJMoa0808431
  5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. https://doi.org/10.1056/NEJMoa072761
  6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35. https://doi.org/10.1016/S0140-6736(09)60953-3
  7. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care 2016;39:738-42. https://doi.org/10.2337/dc15-2237
  8. Ha KH, Kim B, Shin HS, et al. Comparative cardiovascular risks of dipeptidyl peptidase-4 inhibitors: analyses of real-world data in Korea. Korean Circ J 2018;48:395-405. https://doi.org/10.4070/kcj.2017.0324
  9. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. https://doi.org/10.1056/NEJMoa1307684